4314 results about "Long acting" patented technology

The invention discloses an environment-friendly nano water-based silane treatment agent capable of improving anti-corrosion performance of metal surface. The treatment agent is water-based silane solution which consists of at least one alkoxy silane containing epoxy or at least one alkoxy silane containing amino, at least one disilyl silane, nano-silicon dioxide, rare earth salt type corrosion inhibitor or rare earth salt type and rare earth nano oxide, water, or acetic acid and a small amount of ethanol. The metal material is coated by using the silane solution for impregnation, brushing, spraying or spin-coating, a siloxane layer is formed on the metal surface, then the long-acting corrosion resistance is formed by curing for 3 hours at the temperature of 100 DEG C, and a nano organic silane film which has close bonding force with a coating is formed. Nanoparticles can not only improve the corrosion resistance and enhance the mechanical strength of the silane film in a coating layer, but also realize the synergistic corrosion resistance with the corrosion inhibitor. The technology has the advantages of simple process, greenness, environmental protection and strong practicality.

A surgical fastening system, utilizing surgical clips made from bio-absorbable materials, for use in the rapid closing of deep internal wounds in humans or animals is disclosed. Elements of the system include surgical clips, applicators of surgical clips and dispensers of surgical clips. The surgical clips may contain small amounts of prophylactic antibiotic medication, long-acting time-release pain medication, radio-opaque markers, small amounts of radioactive material, colors, and/or patterns.

Use of a growth hormone protein and polynucleotides encoding same comprising an amino-terminal carboxy-terminal peptide (CTP) of chorionic gonadotrophin and two carboxy-terminal chorionic gonadotrophin CTPs attached to the growth hormone in methods of inducing growth or weight gain, method of increasing insulin-like growth factor (IGF-1) levels, and methods of reducing the dosing frequency of a growth hormone in a human subject are disclosed. Pharmaceutical compositions comprising the growth hormone and polynucleotides encoding the growth hormone of the invention and methods of using same are also disclosed.

The present invention relates to compositions and methods for the modulated release of one or more proteins or peptides. The composition is comprised of a biocompatible polymeric matrix, a protein and/or peptide, and a sparingly water-soluble or essentially insoluble particle. The protein is deposited by adsorption or some other mechanism onto the sparingly water-soluble biocompatible particle wherein the protein-particle combination is dispersed within the polymeric matrix. The deposition of the protein onto the particle acts to modulate the release of the protein or peptide from dosage forms including long-acting dosage systems.

The present invention provides a method of treating patients in need of treatment with long acting injectable paliperidone palmitate formulations.

Polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to the carboxy terminus but not to the amino terminus of a coagulation factor and polynucleotides encoding the same are disclosed. Pharmaceutical compositions comprising the polypeptides and polynucleotides of the invention and methods of using and producing same are also disclosed.

Polypeptides and polynucleotides encoding same comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to a carboxy terminus of a coagulation factor and not to an amino terminus are disclosed. Pharmaceutical compositions comprising the polypeptides and polynucleotides of the invention and methods of using same are also disclosed.

The present invention provides sustained release formulations of estradiol metabolites whereby the in vivo pharmacokinetics are manipulated by a method selected from the group consisting of chemical modification, crystal packing formation, particle size or a combination thereof. Such compositions are useful in the long-term treatment of a wide variety of diseases.

In example methods and systems described, insulin therapy for a patient can be determined. At least one of a short-acting subcutaneous insulin dosage recommendation, a correction subcutaneous insulin dosage recommendation, an intravenous insulin dosage recommendation, a recommended amount of carbohydrates to be administered to the patient, or combinations thereof, can be determined. In addition, information indicating a confirmation of a nutrition intake for the patient, and a long-acting insulin-on-board for the patient can be received, and based on this information, a required long-acting subcutaneous or intravenous insulin dosage for the patient can be determined. The short-acting subcutaneous or intravenous insulin dosage recommendation can be adjusted based, at least in part, on a difference between the long-acting insulin-on-board and the required long-acting subcutaneous or intravenous insulin dosage.

The invention relates to nitrogen element fertilizer, in particular to a nitrogen element fertilizer composite synergist and a preparation method thereof. The composite synergist consists of a biochemical inhibitor, a synergist, a nitrogen element stabilizer, a carrier and microelements, the weight portion ratio of the materials is 1:0.01-1: 0.01-0.5: 0.5-1: 0-0.05, wherein the biochemical inhibitor can be a nitrification inhibitor and a urease inhibitor, the synergist can be poly-aspartic acid, and the nitrogen element stabilizer can be hydrolyzed amino acid, humic acid, alginic acid or alginic acid water soluble salt. The preparation method comprises the following steps: crushing the raw materials, screening the raw materials with a sieve of 30 to 100 meshes, and stirring and mixing the raw materials according to the proportion. The nitrogen element fertilizer composite synergist is suitable for growing long acting nitrogenous fertilizer taking urea or ammonium nitrogen fertilizer as raw materials and can be applied to various soils together with urea or ammonium nitrogen fertilizer so as to effectively prolong the fertilizer efficiency period of the urea or the ammonium nitrogen fertilizer. The fertilizer efficiency period can reach 100 to 120 days. The nitrogen element fertilizer composite synergist has remarkable resistance to diseases, drought and lodging, effectively improves the capability of soil to reserve nutrients, and has good effects for off-season crops.

The invention relates to anti-bacterial water-based paint and a preparation method thereof. The paint comprises the following components in parts by weight: 0.2-11 parts of anti-bacterial agent, 8-33 parts of nano material, 23-64 parts of water-based resin dispersoid and 0.75-18 parts of adhesive resin or plasticizer. The preparation method comprises the following steps: firstly preparing a nano silver anti-bacterial agent; mixing deionized water, the anti-bacterial agent, a wetting agent, a dispersing agent and a defoaming agent and uniformly mixing, adding the nano material, uniformly dispersing to obtain the water-based dispersoid; adding the obtained water-based dispersoid to the mixed emulsion or water-based resin dispersoid, then adding the adhesive resin or plasticizer and various conventional assistants, stirring and dispersing evenly; adding pigments or colorant; and supplementing water to obtain the anti-bacterial water-based paint. The long-acting broad-spectrum antibacterial water-based paint has high fungicidal efficiency (more than 99%) on escherichia coli, staphylococcus aureus, black varietas of bacillus subtilis and the like and can reduce the high concentrate of organic matters of formaldehyde to the range of specified concentration index.

A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also disclosed.

A polypeptide and polynucleotides encoding same comprising one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to an amino terminus of a growth hormone and two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a carboxy terminus of a growth hormone are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed.

The invention provides biologically active compounds that may be reacted with macromolecules, such as albumin, to form covalent linked complexes wherein the resulting complexes exhibit a desired biological activity in vivo. More specifically, the complexes are isolated complexes comprising a biologically active moiety covalently bound to a linking group and a protein. The complexes are prepared by conjugating a biologically active moiety, for example, a renin inhibitor or a viral fusion inhibitor peptide, with purified and isolated protein. The complexes have extended lifetimes in the bloodstream as compared to the unconjugated molecule, and exhibit biological activity for extended periods of time as compared to the unconjugated molecule. The invention also provides anti-viral compounds that are inhibitors of viral infection and/or exhibit anti-fusiogenic properties. In particular, this invention provides compounds having inhibiting activity against viruses such as human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) and that have extended duration of action for the treatment of viral infections.

Disclosed are a protein conjugate with improved in vivo duration and stability and the use thereof. The protein conjugate includes a physiologically active polypeptide, a non-peptide polymer and an immunoglobulin Fc fragment. Since the three components are covalently linked, the protein conjugate has extended in vivo duration and enhanced stability for the physiologically active polypeptide. The protein conjugate maintains the in vivo activity at relatively high levels and remarkably increases the serum half-life for the physiologically active polypeptide, with less risk of inducing undesirable immune responses. Thus, the protein conjugate is useful for developing long-acting formulations of various polypeptide drugs.